Last guide line for colon cancer
Reading File
Finding Sources
Searching PubMed
"colon cancer"[MeSH Terms] AND guideline
Searching the Web
2025 colon cancer clinical practice guideline NCCN ASCO ESMO
Reading Web Page
https://www.esmo.org/guidelines/esmo-clinical-practice-guide…
Reading Article
PMID: 38914755
Finding Sources
Latest guidance for colon cancer
Management should be planned by a multidisciplinary colorectal cancer team and based on TNM stage, operability, performance status, and tumour biomarkers, particularly MMR/MSI status.
1. Diagnosis and staging
- Colonoscopy with biopsy and complete colonic assessment where feasible.
- Baseline CEA.
- Contrast CT of chest, abdomen, and pelvis for staging.
- Test every tumour for dMMR/MSI-H status. In metastatic disease, also obtain RAS, BRAF, and HER2 status as appropriate.
2. Localised, resectable colon cancer
- Stage I: Curative surgical resection alone.
- Stage II: Surgery is standard. Consider adjuvant chemotherapy only for high-risk features such as T4 disease, obstruction/perforation, inadequate lymph-node sampling, lymphovascular/perineural invasion, poor differentiation, or tumour budding.
- Do not use fluoropyrimidine-only adjuvant chemotherapy routinely in MSI-H/dMMR stage II tumours.
- Stage III: Surgery followed by oxaliplatin-based adjuvant chemotherapy, usually CAPOX or FOLFOX.
- CAPOX for 3 months may be considered for low-risk stage III disease.
- Higher-risk disease generally receives 6 months, balanced against neuropathy risk.
Surgery remains the mainstay for non-metastatic colon cancer, with adjuvant chemotherapy used in high-risk stage II and stage III disease. Fischer's Mastery of Surgery, 8th ed., Multimodal Therapy. A recent adjuvant-treatment guideline similarly highlights mandatory MMR/MSI testing and stage-specific risk assessment (SEOM-GEMCAD-TTD guideline).
3. Metastatic colon cancer
- Assess whether liver and/or lung metastases are potentially resectable or ablatable.
- For unresectable disease, systemic therapy selection depends on molecular profile:
- MSI-H/dMMR: immune-checkpoint inhibitor therapy is preferred first-line in suitable patients.
- MSS/pMMR: chemotherapy doublets such as FOLFOX, CAPOX, or FOLFIRI, with biologic therapy selected according to RAS/BRAF status and primary tumour sidedness.
- Selected small liver metastases may be treated with resection or thermal ablation in experienced centres.
4. Follow-up after curative treatment
Common surveillance includes:
- History, examination, and CEA every 3-6 months initially, then at longer intervals through 5 years.
- Periodic CT chest/abdomen/pelvis for patients who could undergo treatment for recurrence.
- Colonoscopy at 1 year after surgery, then typically at 3 years and every 5 years if normal.
5. Newer update
The January 2026 ESMO express update recommends offering eligible people with localised colon cancer a structured exercise programme as part of care, and updates the stage II-III adjuvant-treatment algorithm (ESMO update). The main ESMO guideline covers diagnostic work-up, treatment, and follow-up (localised colon cancer guideline).
These are general guideline principles, not an individual treatment plan. Decisions on chemotherapy regimen, duration, and surgery should be made with a colorectal surgeon and medical oncologist.
Last guide line creening for colon cancer
Reading File
Finding Sources
Searching PubMed
"colorectal neoplasms"[MeSH Terms] AND screening
Searching the Web
2026 colorectal cancer screening recommendations USPSTF American Cancer Society screening average risk 45
Latest guidelines: screening for colorectal (colon) cancer
Average-risk, asymptomatic adults
- Start screening at age 45.
- Continue routinely through age 75 if health and life expectancy support benefit.
- Age 76-85: decide individually based on health, prior screening, and preferences.
- Over 85: screening is generally not recommended.
The USPSTF recommendation applies to asymptomatic average-risk adults aged 45 years and older. The 2026 American Cancer Society guideline likewise recommends starting at 45 and continuing to 75 when life expectancy is more than 10 years.
Recommended test options
Any positive non-colonoscopy test requires a diagnostic colonoscopy.
| Screening test | Recommended interval |
|---|---|
| FIT, fecal immunochemical test | Every year |
| High-sensitivity guaiac fecal occult blood test | Every year |
| Multitarget stool DNA test | Every 3 years |
| Multitarget stool RNA test | Every 3 years |
| Colonoscopy | Every 10 years |
| CT colonography | Every 5 years |
| Flexible sigmoidoscopy | Every 5 years |
The best screening test is generally the one the patient is willing and able to complete consistently.
Increased-risk patients
Screening should begin earlier and/or occur more often for people with:
- A first-degree relative with colorectal cancer or advanced adenoma, especially diagnosed before age 60
- Personal history of adenomatous polyps, sessile serrated lesions, or colorectal cancer
- Inflammatory bowel disease involving the colon, such as ulcerative colitis or Crohn colitis
- Lynch syndrome, familial adenomatous polyposis, or another hereditary colorectal cancer syndrome
- Previous abdominal or pelvic radiotherapy.
These groups usually need colonoscopy-based surveillance directed by a gastroenterologist or genetics/oncology team, rather than routine stool testing.
Important distinction
People with warning symptoms, such as rectal bleeding, persistent change in bowel habit, unexplained iron-deficiency anemia, abdominal mass, or unexplained weight loss, need diagnostic evaluation, usually colonoscopy. This is not routine screening.
Recent evidence continues to support screening with stool testing and endoscopic methods; an umbrella review comparing established screening approaches was published in 2025 (systematic review).
Clarify screening for someone with a family history
Reading File
Finding Sources
Searching PubMed
"colorectal neoplasms"[MeSH Terms] AND family history AND screening
Searching the Web
2026 colorectal cancer screening family history first degree relative age 60 guideline American College Gastroenterology
Colon cancer screening when there is a family history
The approach depends on who was affected, what they had, and the age at diagnosis.
| Family history | Screening recommendation |
|---|---|
| One first-degree relative (parent, sibling, child) with colorectal cancer or an advanced polyp diagnosed before age 60 | Colonoscopy every 5 years, starting at age 40 or 10 years before the relative’s diagnosis, whichever comes first |
| Two or more first-degree relatives with colorectal cancer or advanced polyps, at any age | Colonoscopy every 5 years, starting at age 40 or 10 years before the youngest diagnosis, whichever comes first |
| One first-degree relative diagnosed at age 60 or older | Usually screen as average risk, but begin at age 40 in many gastroenterology guidance pathways. Subsequent interval can be average-risk if colonoscopy is normal |
| Only second-degree relatives affected, such as grandparent, aunt, uncle, cousin | Usually average-risk screening: begin at 45, unless the wider pattern suggests a hereditary syndrome |
| Relative had only a non-advanced small tubular adenoma | Usually average-risk screening, because this alone does not clearly raise risk enough to require an early colonoscopy schedule |
For the higher-risk groups, stool tests such as FIT are generally not substitutes for the recommended colonoscopy strategy. The US Multi-Society Task Force advises colonoscopy every 5 years, starting 10 years before the youngest affected relative’s diagnosis or at age 40, whichever comes first, when a first-degree relative was diagnosed before 60 or when two first-degree relatives are affected (MSTF guidance).
When to consider genetic counselling
Referral for genetic assessment is appropriate if there is:
- Colorectal cancer diagnosed before age 50
- Several relatives with colorectal cancer, especially across generations
- A family history of endometrial, ovarian, gastric, pancreatic, urinary tract, or small-bowel cancer
- Numerous colon polyps in a relative
- A known or suspected Lynch syndrome or familial adenomatous polyposis in the family.
A recent meta-analysis confirms that a family history is associated with increased colorectal-neoplasia risk (2025 review).
If you share the relative’s relationship to the person being screened, cancer/polyp type, and age at diagnosis, I can state the appropriate starting age and interval more precisely.
This is a shared conversation. Sign in to Orris to start your own chat.